Advertisment

Decoding the Role of Artificial Intelligence in Oncology and Immunotherapy

author-image
Medriva Correspondents
New Update
NULL

Decoding the Role of Artificial Intelligence in Oncology and Immunotherapy

Advertisment

The portrayal of artificial intelligence (AI) in the media often presents a dystopian future where AI takes over the world. However, in the field of oncology and immunotherapy, AI is not a doom-monger but a potential game-changer. This article aims to shed light on the significant role AI is playing in personalizing immunotherapy, optimizing treatment selection, and improving patient outcomes.

Advertisment

AI in Genomics and Transcriptomics

AI models offer exciting possibilities in genomics, transcriptomics, and epigenomics. These technologies are paving the way for personalized immunotherapy, tailoring treatments to patients' genetic profiles. This personalization has the potential to improve effectiveness and reduce side effects of treatment.

AI in Radiomics and Digital Pathology

Advertisment

The use of AI in radiomics and digital pathology enables early detection and accurate diagnosis of cancer. Machine learning (ML) techniques are also being used to predict the efficacy of cancer immunotherapy. Despite the complexity of cancer and the difficulty in predicting patient prognosis, ML models have demonstrated potential in radiomics, pathomics, and tumor microenvironment (TME) analysis, enhancing the precision of immunotherapy.

AI and Real-world Data

AI algorithms also have a role to play in interpreting real-world and multimodality data. These AI models can analyze electronic health records, imaging, laboratory results, genomics, and more, allowing for a comprehensive understanding of a patient's health status. The proposed Generalist Medical Intelligence (GMAI) could revolutionize treatment planning and delivery, providing a holistic view of the patient's health.

Advertisment

Regulatory Challenges and Solutions

While the potential of AI in oncology is vast, its application is not without challenges. One key hurdle is the regulatory approval process, which is currently lagging behind the rapid advances in AI-based personalized therapies. The existing regulations have been identified as a de facto blocker to AI-based personalized medicine. However, there is a growing recognition of the need for new regulatory thinking, with an emphasis on agility and flexibility, to facilitate the safe and speedy translation of these therapies from bench to bedside.

Glimpses of the Future

The future of AI in oncology is promising, with countries like India already embracing AI for precision oncology. The country's first Precision Oncology Centre powered by AI is now operational, offering individualized care based on genomic data. Meanwhile, collaborations are underway to ensure the protection of sensitive patient data amid growing cybersecurity threats.

However, the journey of AI in oncology is still in its early stages. As more research is conducted and more AI algorithms are validated and tested, the true potential of AI in oncology will be unlocked. Whether it's through personalizing immunotherapy, optimizing treatment selection, or improving patient outcomes, AI is set to transform the field of oncology, turning the dystopian imagery of AI on its head.

Advertisment
Chat with Dr. Medriva !